

# Global Dystrophic Epidermolysis Bullosa Management Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/GC80486F810DEN.html>

Date: March 2023

Pages: 108

Price: US\$ 4,480.00 (Single User License)

ID: GC80486F810DEN

## Abstracts

The global Dystrophic Epidermolysis Bullosa Management market size is expected to reach \$ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

This report studies the global Dystrophic Epidermolysis Bullosa Management demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Dystrophic Epidermolysis Bullosa Management, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Dystrophic Epidermolysis Bullosa Management that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Dystrophic Epidermolysis Bullosa Management total market, 2018-2029, (USD Million)

Global Dystrophic Epidermolysis Bullosa Management total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Dystrophic Epidermolysis Bullosa Management total market, key domestic companies and share, (USD Million)

Global Dystrophic Epidermolysis Bullosa Management revenue by player and market share 2018-2023, (USD Million)

Global Dystrophic Epidermolysis Bullosa Management total market by Type, CAGR, 2018-2029, (USD Million)

Global Dystrophic Epidermolysis Bullosa Management total market by Application, CAGR, 2018-2029, (USD Million)

This reports profiles major players in the global Dystrophic Epidermolysis Bullosa Management market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Castle Creek Biosciences, Amryth Pharma, Krystal Biotech, Abeona Therapeutics, BridgeBio, Phoenix Tissue Repair, Wings Therapeutics, InMed Pharmaceuticals, Inc. and Regenerx Biopharmaceuticals Inc., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Dystrophic Epidermolysis Bullosa Management market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Dystrophic Epidermolysis Bullosa Management Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

### Global Dystrophic Epidermolysis Bullosa Management Market, Segmentation by Type

Dominant Dystrophic Epidermolysis Bullosa (DDEB)

Recessive Dystrophic Epidermolysis Bullosa (RDEB)

### Global Dystrophic Epidermolysis Bullosa Management Market, Segmentation by Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

### Companies Profiled:

Castle Creek Biosciences

Amryth Pharma

Krystal Biotech

Abeona Therapeutics

BridgeBio

Phoenix Tissue Repair

Wings Therapeutics

InMed Pharmaceuticals, Inc.

Regenerx Biopharmaceuticals Inc.

Holostem Therapie Avanzate S.r.l.

### Key Questions Answered

1. How big is the global Dystrophic Epidermolysis Bullosa Management market?
2. What is the demand of the global Dystrophic Epidermolysis Bullosa Management market?
3. What is the year over year growth of the global Dystrophic Epidermolysis Bullosa Management market?
4. What is the total value of the global Dystrophic Epidermolysis Bullosa Management market?
5. Who are the major players in the global Dystrophic Epidermolysis Bullosa Management market?
6. What are the growth factors driving the market demand?

## Contents

### 1 SUPPLY SUMMARY

- 1.1 Dystrophic Epidermolysis Bullosa Management Introduction
- 1.2 World Dystrophic Epidermolysis Bullosa Management Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Dystrophic Epidermolysis Bullosa Management Total Market by Region (by Headquarter Location)
  - 1.3.1 World Dystrophic Epidermolysis Bullosa Management Market Size by Region (2018-2029), (by Headquarter Location)
  - 1.3.2 United States Dystrophic Epidermolysis Bullosa Management Market Size (2018-2029)
  - 1.3.3 China Dystrophic Epidermolysis Bullosa Management Market Size (2018-2029)
  - 1.3.4 Europe Dystrophic Epidermolysis Bullosa Management Market Size (2018-2029)
  - 1.3.5 Japan Dystrophic Epidermolysis Bullosa Management Market Size (2018-2029)
  - 1.3.6 South Korea Dystrophic Epidermolysis Bullosa Management Market Size (2018-2029)
  - 1.3.7 ASEAN Dystrophic Epidermolysis Bullosa Management Market Size (2018-2029)
  - 1.3.8 India Dystrophic Epidermolysis Bullosa Management Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
  - 1.4.1 Dystrophic Epidermolysis Bullosa Management Market Drivers
  - 1.4.2 Factors Affecting Demand
  - 1.4.3 Dystrophic Epidermolysis Bullosa Management Major Market Trends
- 1.5 Influence of COVID-19 and Russia-Ukraine War
  - 1.5.1 Influence of COVID-19
  - 1.5.2 Influence of Russia-Ukraine War

### 2 DEMAND SUMMARY

- 2.1 World Dystrophic Epidermolysis Bullosa Management Consumption Value (2018-2029)
- 2.2 World Dystrophic Epidermolysis Bullosa Management Consumption Value by Region
  - 2.2.1 World Dystrophic Epidermolysis Bullosa Management Consumption Value by Region (2018-2023)
  - 2.2.2 World Dystrophic Epidermolysis Bullosa Management Consumption Value Forecast by Region (2024-2029)
- 2.3 United States Dystrophic Epidermolysis Bullosa Management Consumption Value

(2018-2029)

2.4 China Dystrophic Epidermolysis Bullosa Management Consumption Value

(2018-2029)

2.5 Europe Dystrophic Epidermolysis Bullosa Management Consumption Value

(2018-2029)

2.6 Japan Dystrophic Epidermolysis Bullosa Management Consumption Value

(2018-2029)

2.7 South Korea Dystrophic Epidermolysis Bullosa Management Consumption Value

(2018-2029)

2.8 ASEAN Dystrophic Epidermolysis Bullosa Management Consumption Value

(2018-2029)

2.9 India Dystrophic Epidermolysis Bullosa Management Consumption Value

(2018-2029)

### **3 WORLD DYSTROPHIC EPIDERMOLYSIS BULLOSA MANAGEMENT COMPANIES COMPETITIVE ANALYSIS**

3.1 World Dystrophic Epidermolysis Bullosa Management Revenue by Player

(2018-2023)

3.2 Industry Rank and Concentration Rate (CR)

3.2.1 Global Dystrophic Epidermolysis Bullosa Management Industry Rank of Major Players

3.2.2 Global Concentration Ratios (CR4) for Dystrophic Epidermolysis Bullosa Management in 2022

3.2.3 Global Concentration Ratios (CR8) for Dystrophic Epidermolysis Bullosa Management in 2022

3.3 Dystrophic Epidermolysis Bullosa Management Company Evaluation Quadrant

3.4 Dystrophic Epidermolysis Bullosa Management Market: Overall Company Footprint Analysis

3.4.1 Dystrophic Epidermolysis Bullosa Management Market: Region Footprint

3.4.2 Dystrophic Epidermolysis Bullosa Management Market: Company Product Type Footprint

3.4.3 Dystrophic Epidermolysis Bullosa Management Market: Company Product Application Footprint

3.5 Competitive Environment

3.5.1 Historical Structure of the Industry

3.5.2 Barriers of Market Entry

3.5.3 Factors of Competition

3.6 Mergers, Acquisitions Activity

## **4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)**

4.1 United States VS China: Dystrophic Epidermolysis Bullosa Management Revenue Comparison (by Headquarter Location)

4.1.1 United States VS China: Dystrophic Epidermolysis Bullosa Management Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)

4.1.2 United States VS China: Dystrophic Epidermolysis Bullosa Management Revenue Market Share Comparison (2018 & 2022 & 2029)

4.2 United States Based Companies VS China Based Companies: Dystrophic Epidermolysis Bullosa Management Consumption Value Comparison

4.2.1 United States VS China: Dystrophic Epidermolysis Bullosa Management Consumption Value Comparison (2018 & 2022 & 2029)

4.2.2 United States VS China: Dystrophic Epidermolysis Bullosa Management Consumption Value Market Share Comparison (2018 & 2022 & 2029)

4.3 United States Based Dystrophic Epidermolysis Bullosa Management Companies and Market Share, 2018-2023

4.3.1 United States Based Dystrophic Epidermolysis Bullosa Management Companies, Headquarters (States, Country)

4.3.2 United States Based Companies Dystrophic Epidermolysis Bullosa Management Revenue, (2018-2023)

4.4 China Based Companies Dystrophic Epidermolysis Bullosa Management Revenue and Market Share, 2018-2023

4.4.1 China Based Dystrophic Epidermolysis Bullosa Management Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies Dystrophic Epidermolysis Bullosa Management Revenue, (2018-2023)

4.5 Rest of World Based Dystrophic Epidermolysis Bullosa Management Companies and Market Share, 2018-2023

4.5.1 Rest of World Based Dystrophic Epidermolysis Bullosa Management Companies, Headquarters (States, Country)

4.5.2 Rest of World Based Companies Dystrophic Epidermolysis Bullosa Management Revenue, (2018-2023)

## **5 MARKET ANALYSIS BY TYPE**

5.1 World Dystrophic Epidermolysis Bullosa Management Market Size Overview by Type: 2018 VS 2022 VS 2029

## 5.2 Segment Introduction by Type

5.2.1 Dominant Dystrophic Epidermolysis Bullosa (DDEB)

5.2.2 Recessive Dystrophic Epidermolysis Bullosa (RDEB)

## 5.3 Market Segment by Type

5.3.1 World Dystrophic Epidermolysis Bullosa Management Market Size by Type (2018-2023)

5.3.2 World Dystrophic Epidermolysis Bullosa Management Market Size by Type (2024-2029)

5.3.3 World Dystrophic Epidermolysis Bullosa Management Market Size Market Share by Type (2018-2029)

## 6 MARKET ANALYSIS BY APPLICATION

6.1 World Dystrophic Epidermolysis Bullosa Management Market Size Overview by Application: 2018 VS 2022 VS 2029

### 6.2 Segment Introduction by Application

6.2.1 Hospital Pharmacies

6.2.2 Retail Pharmacies

6.2.3 Online Pharmacies

### 6.3 Market Segment by Application

6.3.1 World Dystrophic Epidermolysis Bullosa Management Market Size by Application (2018-2023)

6.3.2 World Dystrophic Epidermolysis Bullosa Management Market Size by Application (2024-2029)

6.3.3 World Dystrophic Epidermolysis Bullosa Management Market Size by Application (2018-2029)

## 7 COMPANY PROFILES

### 7.1 Castle Creek Biosciences

7.1.1 Castle Creek Biosciences Details

7.1.2 Castle Creek Biosciences Major Business

7.1.3 Castle Creek Biosciences Dystrophic Epidermolysis Bullosa Management Product and Services

7.1.4 Castle Creek Biosciences Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023)

7.1.5 Castle Creek Biosciences Recent Developments/Updates

7.1.6 Castle Creek Biosciences Competitive Strengths & Weaknesses

### 7.2 Amryth Pharma



- 7.2.1 Amryth Pharma Details
- 7.2.2 Amryth Pharma Major Business
- 7.2.3 Amryth Pharma Dystrophic Epidermolysis Bullosa Management Product and Services
- 7.2.4 Amryth Pharma Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023)
- 7.2.5 Amryth Pharma Recent Developments/Updates
- 7.2.6 Amryth Pharma Competitive Strengths & Weaknesses
- 7.3 Krystal Biotech
  - 7.3.1 Krystal Biotech Details
  - 7.3.2 Krystal Biotech Major Business
  - 7.3.3 Krystal Biotech Dystrophic Epidermolysis Bullosa Management Product and Services
  - 7.3.4 Krystal Biotech Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023)
  - 7.3.5 Krystal Biotech Recent Developments/Updates
  - 7.3.6 Krystal Biotech Competitive Strengths & Weaknesses
- 7.4 Abeona Therapeutics
  - 7.4.1 Abeona Therapeutics Details
  - 7.4.2 Abeona Therapeutics Major Business
  - 7.4.3 Abeona Therapeutics Dystrophic Epidermolysis Bullosa Management Product and Services
  - 7.4.4 Abeona Therapeutics Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023)
  - 7.4.5 Abeona Therapeutics Recent Developments/Updates
  - 7.4.6 Abeona Therapeutics Competitive Strengths & Weaknesses
- 7.5 BridgeBio
  - 7.5.1 BridgeBio Details
  - 7.5.2 BridgeBio Major Business
  - 7.5.3 BridgeBio Dystrophic Epidermolysis Bullosa Management Product and Services
  - 7.5.4 BridgeBio Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023)
  - 7.5.5 BridgeBio Recent Developments/Updates
  - 7.5.6 BridgeBio Competitive Strengths & Weaknesses
- 7.6 Phoenix Tissue Repair
  - 7.6.1 Phoenix Tissue Repair Details
  - 7.6.2 Phoenix Tissue Repair Major Business
  - 7.6.3 Phoenix Tissue Repair Dystrophic Epidermolysis Bullosa Management Product and Services

7.6.4 Phoenix Tissue Repair Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023)

7.6.5 Phoenix Tissue Repair Recent Developments/Updates

7.6.6 Phoenix Tissue Repair Competitive Strengths & Weaknesses

7.7 Wings Therapeutics

7.7.1 Wings Therapeutics Details

7.7.2 Wings Therapeutics Major Business

7.7.3 Wings Therapeutics Dystrophic Epidermolysis Bullosa Management Product and Services

7.7.4 Wings Therapeutics Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023)

7.7.5 Wings Therapeutics Recent Developments/Updates

7.7.6 Wings Therapeutics Competitive Strengths & Weaknesses

7.8 InMed Pharmaceuticals, Inc.

7.8.1 InMed Pharmaceuticals, Inc. Details

7.8.2 InMed Pharmaceuticals, Inc. Major Business

7.8.3 InMed Pharmaceuticals, Inc. Dystrophic Epidermolysis Bullosa Management Product and Services

7.8.4 InMed Pharmaceuticals, Inc. Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023)

7.8.5 InMed Pharmaceuticals, Inc. Recent Developments/Updates

7.8.6 InMed Pharmaceuticals, Inc. Competitive Strengths & Weaknesses

7.9 Regenerx Biopharmaceuticals Inc.

7.9.1 Regenerx Biopharmaceuticals Inc. Details

7.9.2 Regenerx Biopharmaceuticals Inc. Major Business

7.9.3 Regenerx Biopharmaceuticals Inc. Dystrophic Epidermolysis Bullosa Management Product and Services

7.9.4 Regenerx Biopharmaceuticals Inc. Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023)

7.9.5 Regenerx Biopharmaceuticals Inc. Recent Developments/Updates

7.9.6 Regenerx Biopharmaceuticals Inc. Competitive Strengths & Weaknesses

7.10 Holostem Terapie Avanzate S.r.l.

7.10.1 Holostem Terapie Avanzate S.r.l. Details

7.10.2 Holostem Terapie Avanzate S.r.l. Major Business

7.10.3 Holostem Terapie Avanzate S.r.l. Dystrophic Epidermolysis Bullosa Management Product and Services

7.10.4 Holostem Terapie Avanzate S.r.l. Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023)

7.10.5 Holostem Terapie Avanzate S.r.l. Recent Developments/Updates

#### 7.10.6 Holostem Terapie Avanzate S.r.l. Competitive Strengths & Weaknesses

### **8 INDUSTRY CHAIN ANALYSIS**

8.1 Dystrophic Epidermolysis Bullosa Management Industry Chain

8.2 Dystrophic Epidermolysis Bullosa Management Upstream Analysis

8.3 Dystrophic Epidermolysis Bullosa Management Midstream Analysis

8.4 Dystrophic Epidermolysis Bullosa Management Downstream Analysis

### **9 RESEARCH FINDINGS AND CONCLUSION**

### **10 APPENDIX**

10.1 Methodology

10.2 Research Process and Data Source

10.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. World Dystrophic Epidermolysis Bullosa Management Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Table 2. World Dystrophic Epidermolysis Bullosa Management Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)

Table 3. World Dystrophic Epidermolysis Bullosa Management Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)

Table 4. World Dystrophic Epidermolysis Bullosa Management Revenue Market Share by Region (2018-2023), (by Headquarter Location)

Table 5. World Dystrophic Epidermolysis Bullosa Management Revenue Market Share by Region (2024-2029), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Dystrophic Epidermolysis Bullosa Management Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)

Table 8. World Dystrophic Epidermolysis Bullosa Management Consumption Value by Region (2018-2023) & (USD Million)

Table 9. World Dystrophic Epidermolysis Bullosa Management Consumption Value Forecast by Region (2024-2029) & (USD Million)

Table 10. World Dystrophic Epidermolysis Bullosa Management Revenue by Player (2018-2023) & (USD Million)

Table 11. Revenue Market Share of Key Dystrophic Epidermolysis Bullosa Management Players in 2022

Table 12. World Dystrophic Epidermolysis Bullosa Management Industry Rank of Major Player, Based on Revenue in 2022

Table 13. Global Dystrophic Epidermolysis Bullosa Management Company Evaluation Quadrant

Table 14. Head Office of Key Dystrophic Epidermolysis Bullosa Management Player

Table 15. Dystrophic Epidermolysis Bullosa Management Market: Company Product Type Footprint

Table 16. Dystrophic Epidermolysis Bullosa Management Market: Company Product Application Footprint

Table 17. Dystrophic Epidermolysis Bullosa Management Mergers & Acquisitions Activity

Table 18. United States VS China Dystrophic Epidermolysis Bullosa Management Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 19. United States VS China Dystrophic Epidermolysis Bullosa Management

Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 20. United States Based Dystrophic Epidermolysis Bullosa Management Companies, Headquarters (States, Country)

Table 21. United States Based Companies Dystrophic Epidermolysis Bullosa Management Revenue, (2018-2023) & (USD Million)

Table 22. United States Based Companies Dystrophic Epidermolysis Bullosa Management Revenue Market Share (2018-2023)

Table 23. China Based Dystrophic Epidermolysis Bullosa Management Companies, Headquarters (Province, Country)

Table 24. China Based Companies Dystrophic Epidermolysis Bullosa Management Revenue, (2018-2023) & (USD Million)

Table 25. China Based Companies Dystrophic Epidermolysis Bullosa Management Revenue Market Share (2018-2023)

Table 26. Rest of World Based Dystrophic Epidermolysis Bullosa Management Companies, Headquarters (States, Country)

Table 27. Rest of World Based Companies Dystrophic Epidermolysis Bullosa Management Revenue, (2018-2023) & (USD Million)

Table 28. Rest of World Based Companies Dystrophic Epidermolysis Bullosa Management Revenue Market Share (2018-2023)

Table 29. World Dystrophic Epidermolysis Bullosa Management Market Size by Type, (USD Million), 2018 & 2022 & 2029

Table 30. World Dystrophic Epidermolysis Bullosa Management Market Size by Type (2018-2023) & (USD Million)

Table 31. World Dystrophic Epidermolysis Bullosa Management Market Size by Type (2024-2029) & (USD Million)

Table 32. World Dystrophic Epidermolysis Bullosa Management Market Size by Application, (USD Million), 2018 & 2022 & 2029

Table 33. World Dystrophic Epidermolysis Bullosa Management Market Size by Application (2018-2023) & (USD Million)

Table 34. World Dystrophic Epidermolysis Bullosa Management Market Size by Application (2024-2029) & (USD Million)

Table 35. Castle Creek Biosciences Basic Information, Area Served and Competitors

Table 36. Castle Creek Biosciences Major Business

Table 37. Castle Creek Biosciences Dystrophic Epidermolysis Bullosa Management Product and Services

Table 38. Castle Creek Biosciences Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 39. Castle Creek Biosciences Recent Developments/Updates

Table 40. Castle Creek Biosciences Competitive Strengths & Weaknesses

- Table 41. Amryth Pharma Basic Information, Area Served and Competitors
- Table 42. Amryth Pharma Major Business
- Table 43. Amryth Pharma Dystrophic Epidermolysis Bullosa Management Product and Services
- Table 44. Amryth Pharma Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 45. Amryth Pharma Recent Developments/Updates
- Table 46. Amryth Pharma Competitive Strengths & Weaknesses
- Table 47. Krystal Biotech Basic Information, Area Served and Competitors
- Table 48. Krystal Biotech Major Business
- Table 49. Krystal Biotech Dystrophic Epidermolysis Bullosa Management Product and Services
- Table 50. Krystal Biotech Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 51. Krystal Biotech Recent Developments/Updates
- Table 52. Krystal Biotech Competitive Strengths & Weaknesses
- Table 53. Abeona Therapeutics Basic Information, Area Served and Competitors
- Table 54. Abeona Therapeutics Major Business
- Table 55. Abeona Therapeutics Dystrophic Epidermolysis Bullosa Management Product and Services
- Table 56. Abeona Therapeutics Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 57. Abeona Therapeutics Recent Developments/Updates
- Table 58. Abeona Therapeutics Competitive Strengths & Weaknesses
- Table 59. BridgeBio Basic Information, Area Served and Competitors
- Table 60. BridgeBio Major Business
- Table 61. BridgeBio Dystrophic Epidermolysis Bullosa Management Product and Services
- Table 62. BridgeBio Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 63. BridgeBio Recent Developments/Updates
- Table 64. BridgeBio Competitive Strengths & Weaknesses
- Table 65. Phoenix Tissue Repair Basic Information, Area Served and Competitors
- Table 66. Phoenix Tissue Repair Major Business
- Table 67. Phoenix Tissue Repair Dystrophic Epidermolysis Bullosa Management Product and Services
- Table 68. Phoenix Tissue Repair Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 69. Phoenix Tissue Repair Recent Developments/Updates



- Table 70. Phoenix Tissue Repair Competitive Strengths & Weaknesses
- Table 71. Wings Therapeutics Basic Information, Area Served and Competitors
- Table 72. Wings Therapeutics Major Business
- Table 73. Wings Therapeutics Dystrophic Epidermolysis Bullosa Management Product and Services
- Table 74. Wings Therapeutics Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 75. Wings Therapeutics Recent Developments/Updates
- Table 76. Wings Therapeutics Competitive Strengths & Weaknesses
- Table 77. InMed Pharmaceuticals, Inc. Basic Information, Area Served and Competitors
- Table 78. InMed Pharmaceuticals, Inc. Major Business
- Table 79. InMed Pharmaceuticals, Inc. Dystrophic Epidermolysis Bullosa Management Product and Services
- Table 80. InMed Pharmaceuticals, Inc. Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 81. InMed Pharmaceuticals, Inc. Recent Developments/Updates
- Table 82. InMed Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
- Table 83. Regenerx Biopharmaceuticals Inc. Basic Information, Area Served and Competitors
- Table 84. Regenerx Biopharmaceuticals Inc. Major Business
- Table 85. Regenerx Biopharmaceuticals Inc. Dystrophic Epidermolysis Bullosa Management Product and Services
- Table 86. Regenerx Biopharmaceuticals Inc. Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 87. Regenerx Biopharmaceuticals Inc. Recent Developments/Updates
- Table 88. Holostem Therapie Avanzate S.r.l. Basic Information, Area Served and Competitors
- Table 89. Holostem Therapie Avanzate S.r.l. Major Business
- Table 90. Holostem Therapie Avanzate S.r.l. Dystrophic Epidermolysis Bullosa Management Product and Services
- Table 91. Holostem Therapie Avanzate S.r.l. Dystrophic Epidermolysis Bullosa Management Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 92. Global Key Players of Dystrophic Epidermolysis Bullosa Management Upstream (Raw Materials)
- Table 93. Dystrophic Epidermolysis Bullosa Management Typical Customers

## List Of Figures

### LIST OF FIGURES

- Figure 1. Dystrophic Epidermolysis Bullosa Management Picture
- Figure 2. World Dystrophic Epidermolysis Bullosa Management Total Market Size: 2018 & 2022 & 2029, (USD Million)
- Figure 3. World Dystrophic Epidermolysis Bullosa Management Total Market Size (2018-2029) & (USD Million)
- Figure 4. World Dystrophic Epidermolysis Bullosa Management Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
- Figure 5. World Dystrophic Epidermolysis Bullosa Management Revenue Market Share by Region (2018-2029), (by Headquarter Location)
- Figure 6. United States Based Company Dystrophic Epidermolysis Bullosa Management Revenue (2018-2029) & (USD Million)
- Figure 7. China Based Company Dystrophic Epidermolysis Bullosa Management Revenue (2018-2029) & (USD Million)
- Figure 8. Europe Based Company Dystrophic Epidermolysis Bullosa Management Revenue (2018-2029) & (USD Million)
- Figure 9. Japan Based Company Dystrophic Epidermolysis Bullosa Management Revenue (2018-2029) & (USD Million)
- Figure 10. South Korea Based Company Dystrophic Epidermolysis Bullosa Management Revenue (2018-2029) & (USD Million)
- Figure 11. ASEAN Based Company Dystrophic Epidermolysis Bullosa Management Revenue (2018-2029) & (USD Million)
- Figure 12. India Based Company Dystrophic Epidermolysis Bullosa Management Revenue (2018-2029) & (USD Million)
- Figure 13. Dystrophic Epidermolysis Bullosa Management Market Drivers
- Figure 14. Factors Affecting Demand
- Figure 15. World Dystrophic Epidermolysis Bullosa Management Consumption Value (2018-2029) & (USD Million)
- Figure 16. World Dystrophic Epidermolysis Bullosa Management Consumption Value Market Share by Region (2018-2029)
- Figure 17. United States Dystrophic Epidermolysis Bullosa Management Consumption Value (2018-2029) & (USD Million)
- Figure 18. China Dystrophic Epidermolysis Bullosa Management Consumption Value (2018-2029) & (USD Million)
- Figure 19. Europe Dystrophic Epidermolysis Bullosa Management Consumption Value (2018-2029) & (USD Million)



Figure 20. Japan Dystrophic Epidermolysis Bullosa Management Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Dystrophic Epidermolysis Bullosa Management Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Dystrophic Epidermolysis Bullosa Management Consumption Value (2018-2029) & (USD Million)

Figure 23. India Dystrophic Epidermolysis Bullosa Management Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of Dystrophic Epidermolysis Bullosa Management by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for Dystrophic Epidermolysis Bullosa Management Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Dystrophic Epidermolysis Bullosa Management Markets in 2022

Figure 27. United States VS China: Dystrophic Epidermolysis Bullosa Management Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Dystrophic Epidermolysis Bullosa Management Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Dystrophic Epidermolysis Bullosa Management Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Dystrophic Epidermolysis Bullosa Management Market Size Market Share by Type in 2022

Figure 31. Dominant Dystrophic Epidermolysis Bullosa (DDEB)

Figure 32. Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Figure 33. World Dystrophic Epidermolysis Bullosa Management Market Size Market Share by Type (2018-2029)

Figure 34. World Dystrophic Epidermolysis Bullosa Management Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 35. World Dystrophic Epidermolysis Bullosa Management Market Size Market Share by Application in 2022

Figure 36. Hospital Pharmacies

Figure 37. Retail Pharmacies

Figure 38. Online Pharmacies

Figure 39. Dystrophic Epidermolysis Bullosa Management Industrial Chain

Figure 40. Methodology

Figure 41. Research Process and Data Source

## I would like to order

Product name: Global Dystrophic Epidermolysis Bullosa Management Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/GC80486F810DEN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC80486F810DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

